BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 32220548)

  • 1. Bioptic intraprostatic chronic inflammation predicts adverse pathology at radical prostatectomy in patients with low-grade prostate cancer.
    Sanguedolce F; Falagario UG; Castellan P; Di Nauta M; Silecchia G; Bruno SM; Russo D; Treacy PJ; Tewari AK; Montironi R; Carrieri G; Cormio L
    Urol Oncol; 2020 Oct; 38(10):793.e19-793.e25. PubMed ID: 32220548
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical significance and risk factors of International Society of Urological Pathology (ISUP) grade upgrading in prostate cancer patients undergoing robot-assisted radical prostatectomy.
    Takeshima Y; Yamada Y; Teshima T; Fujimura T; Kakutani S; Hakozaki Y; Kimura N; Akiyama Y; Sato Y; Kawai T; Yamada D; Kume H
    BMC Cancer; 2021 May; 21(1):501. PubMed ID: 33947348
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel nomogram to identify candidates for active surveillance amongst patients with International Society of Urological Pathology (ISUP) Grade Group (GG) 1 or ISUP GG2 prostate cancer, according to multiparametric magnetic resonance imaging findings.
    Luzzago S; de Cobelli O; Cozzi G; Peveri G; Bagnardi V; Catellani M; Di Trapani E; Mistretta FA; Pricolo P; Conti A; Alessi S; Marvaso G; Ferro M; Matei DV; Renne G; Jereczek-Fossa BA; Petralia G; Musi G
    BJU Int; 2020 Jul; 126(1):104-113. PubMed ID: 32150328
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Accuracy of prostate biopsies for predicting Gleason score in radical prostatectomy specimens: nationwide trends 2000-2012.
    Danneman D; Drevin L; Delahunt B; Samaratunga H; Robinson D; Bratt O; Loeb S; Stattin P; Egevad L
    BJU Int; 2017 Jan; 119(1):50-56. PubMed ID: 26918298
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The ability of prostate-specific antigen (PSA) density to predict an upgrade in Gleason score between initial prostate biopsy and prostatectomy diminishes with increasing tumour grade due to reduced PSA secretion per unit tumour volume.
    Corcoran NM; Casey RG; Hong MK; Pedersen J; Connolly S; Peters J; Harewood L; Gleave ME; Costello AJ; Hovens CM; Goldenberg SL
    BJU Int; 2012 Jul; 110(1):36-42. PubMed ID: 22085203
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathological upgrading in prostate cancer patients eligible for active surveillance: Does prostate-specific antigen density matter?
    Jin BS; Kang SH; Kim DY; Oh HG; Kim CI; Moon GH; Kwon TG; Park JS
    Korean J Urol; 2015 Sep; 56(9):624-9. PubMed ID: 26366274
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinicopathological factors associated with pathological upgrading from biopsy to prostatectomy in patients with ISUP grade group ≤2 prostate cancer.
    Li X; Wang ZX; Zhu YP; Wang J; Yin YS; Zeng XY
    Asian J Androl; 2022; 24(5):487-493. PubMed ID: 35170453
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predicting the risk of harboring high-grade disease for patients diagnosed with prostate cancer scored as Gleason ≤ 6 on biopsy cores.
    Seisen T; Roudot-Thoraval F; Bosset PO; Beaugerie A; Allory Y; Vordos D; Abbou CC; De La Taille A; Salomon L
    World J Urol; 2015 Jun; 33(6):787-92. PubMed ID: 24985552
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of prostate health index to predict Gleason score upgrading and high-risk prostate cancer in radical prostatectomy specimens.
    Kim H; Jung G; Kim JH; Byun SS; Hong SK
    Sci Rep; 2021 Aug; 11(1):17447. PubMed ID: 34465825
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of the 2005 International Society of Urological Pathology consensus guidelines on Gleason grading - a matched-pair analysis.
    Berg KD; Thomsen FB; Nerstrøm C; Røder MA; Iversen P; Toft BG; Vainer B; Brasso K
    BJU Int; 2016 Jun; 117(6):883-9. PubMed ID: 26823232
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathological findings at radical prostatectomy of biopsy naïve men diagnosed with MRI targeted biopsy alone without concomitant standard systematic sampling.
    Luzzago S; Petralia G; Maresca D; Sabatini I; Cordima G; Brescia A; Verweij F; Garelli G; Mistretta FA; Cioffi A; Pricolo P; Alessi S; Ferro M; Matei DV; Renne G; de Cobelli O; Musi G
    Urol Oncol; 2020 Dec; 38(12):929.e11-929.e19. PubMed ID: 32600928
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Concordance of biopsy and pathologic ISUP grading in salvage radical prostatectomy patients for recurrent prostate cancer.
    Preisser F; Würnschimmel C; Pose RM; Heinze A; Steuber T; Michl U; Salomon G; Mandel P; Graefen M; Tilki D
    Prostate; 2022 Feb; 82(2):254-259. PubMed ID: 34807461
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prostate-specific antigen vs prostate-specific antigen density as a predictor of upgrading in men diagnosed with Gleason 6 prostate cancer by contemporary multicore prostate biopsy.
    Oh JJ; Hong SK; Lee JK; Lee BK; Lee S; Kwon OS; Byun SS; Lee SE
    BJU Int; 2012 Dec; 110(11 Pt B):E494-9. PubMed ID: 22540236
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low-volume grade group 2 prostate cancer candidates for active surveillance: a radical prostatectomy retrospective analysis.
    Björklund J; Cheung DC; Martin LJ; Komisarenko M; Lajkosz K; Hamilton RJ; Zlotta AR; Finelli A
    Scand J Urol; 2023; 57(1-6):29-35. PubMed ID: 36683418
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preoperative characteristics of high-Gleason disease predictive of favourable pathological and clinical outcomes at radical prostatectomy.
    Pierorazio PM; Ross AE; Lin BM; Epstein JI; Han M; Walsh PC; Partin AW; Pavlovich CP; Schaeffer EM
    BJU Int; 2012 Oct; 110(8):1122-8. PubMed ID: 22373045
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk and predictors of adverse pathology after radical prostatectomy in patients diagnosed with IUSP 1-2 prostate cancer at MRI-targeted biopsy: a multicenter analysis.
    Kesch C; Pantea V; Soeterik T; Marquis A; la Bombarda G; Morlacco A; Barletta F; Radtke JP; Darr C; Preisser F; Zattoni F; Marra G; van den Bergh RCN; Hadaschik B; Gandaglia G;
    World J Urol; 2023 Feb; 41(2):427-434. PubMed ID: 36534151
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The clinical predictive factors and postoperative histopathological parameters associated with upgrading after radical prostatectomy: A contemporary analysis with grade groups.
    Erdem S; Verep S; Bagbudar S; Ozluk Y; Sanli O; Ozcan F
    Prostate; 2020 Feb; 80(2):225-234. PubMed ID: 31794085
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biparametric Prostate Imaging Reporting and Data System version2 and International Society of Urological Pathology Grade Predict Biochemical Recurrence after Radical Prostatectomy.
    Takeuchi N; Sakamoto S; Nishiyama A; Horikoshi T; Yamada Y; Iizuka J; Maimaiti M; Imamura Y; Kawamura K; Imamoto T; Komiya A; Ikehara Y; Akakura K; Ichikawa T
    Clin Genitourin Cancer; 2018 Aug; 16(4):e817-e829. PubMed ID: 29576444
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adverse Disease Features in Gleason Score 3 + 4 "Favorable Intermediate-Risk" Prostate Cancer: Implications for Active Surveillance.
    Morlacco A; Cheville JC; Rangel LJ; Gearman DJ; Karnes RJ
    Eur Urol; 2017 Sep; 72(3):442-447. PubMed ID: 27574819
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictive value of four kallikrein markers for pathologically insignificant compared with aggressive prostate cancer in radical prostatectomy specimens: results from the European Randomized Study of Screening for Prostate Cancer section Rotterdam.
    Carlsson S; Maschino A; Schröder F; Bangma C; Steyerberg EW; van der Kwast T; van Leenders G; Vickers A; Lilja H; Roobol MJ
    Eur Urol; 2013 Nov; 64(5):693-9. PubMed ID: 23683475
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.